Stavudine Toxicity in Adult Longer-Term ART Patients in Blantyre, Malawi

Malawi-Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
PLoS ONE (Impact Factor: 3.53). 07/2012; 7(7):e42029. DOI: 10.1371/journal.pone.0042029
Source: PubMed

ABSTRACT Stavudine is an effective and inexpensive antiretroviral drug, but no longer recommended by WHO for first-line antiretroviral regimens in resource-limited settings due to toxicity concerns. Because of the high cost of alternative drugs, it has not been feasible to replace stavudine in most adults in the Malawi ART programme. We aimed to provide policy makers with a detailed picture of stavudine toxicities in Malawians on longer-term ART, in order to facilitate prioritization of stavudine replacement among other measures to improve the quality of ART programmes.
Prospective cohort of Malawian adults who had just completed one year of stavudine containing ART in an urban clinic, studying peripheral neuropathy, lipodystrophy, diabetes mellitus, high lactate syndromes, pancreatitis and dyslipidemia during 12 months follow up. Stavudine dosage was 30 mg irrespective of weight. Cox regression was used to determine associations with incident toxicities.
253 patients were enrolled, median age 36 years, 62.5% females. Prevalence rates (95%-confidence interval) of toxicities after one year on stavudine were: peripheral neuropathy 21.3% (16.5-26.9), lipodystrophy 14.7% (2.4-8.1), high lactate syndromes 0.0% (0-1.4), diabetes mellitus 0.8% (0-2.8), pancreatitis 0.0% (0-1.5). Incidence rates per 100 person-years (95%-confidence interval) during the second year on stavudine were: peripheral neuropathy 19.8 (14.3-26.6), lipodystrophy 11.4 (7.5-16.3), high lactate syndromes 2.1 (0.7-4.9), diabetes mellitus 0.4 (0.0-1.4), pancreatitis 0.0 (0.0-0.2). Prevalence of hypercholesterolemia and hypertriglyceridemia increased from 12.1% to 21.1% and from 29.5% to 37.6% respectively between 12 and 24 months. 5.5% stopped stavudine, 1.3% died and 4.0% defaulted during follow up. Higher age was an independent risk factor for incident peripheral neuropathy and lipodystrophy.
Stavudine associated toxicities continued to accumulate during the second year of ART, especially peripheral neuropathy and lipodystrophy and more so at increasing age. Our findings support investments for replacing stavudine in first-line regimens in sub-Saharan Africa.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background/Aim. Highly active antiretroviral therapy (HAART) has led to dramatic reductions in mortality and morbidity of HIV/AIDS-patients. Lipodystrophy, a syndrome including peripheral fat wasting and central obesity, is well-documented side effect of HAART. The aim of this study was to evaluate the incidence of lipodystrophy, and to determine its risk ratios in a HIV/AIDS-cohort. Methods. This cross-sectional study included all the antiretroviralnaive HIV/AIDS patients commencing HAART from October 1, 2001 to October 1, 2010, at the HIV/AIDS Center, Institute of Infectious and Tropical Diseases, Belgrade, Serbia. Univariate and stepwise multivariate logistic regression analyses were used to determine the odds ratios (OR) with the confidence interval (Cl) of 95%, in order to establish the relative risk for lipodystrophy. The Kaplan-Meier-method was used to determine the probability of development lipodystrophy over time. All statistical analyses were performed using SPSS software version using 0.05 as a p-treshold for the significance. Results. This study ineluded 840 HIV/AIDS patients, 608 women and 232 men, followed for 5.6 +/- 2.8 years. The prevalence of lipodystrophy was 69.2%. Univariate and stepwise multivariate regression analysis identified that the female gender, hepatitis C coinfection, AIDS diagnosis prior to HAART initiation, nucleoside-reverse-transcriptase-inhibitors and protease-inhibitors based regimens had a high risk for developing lipodystrophy in HIV/AIDS-patients (OR = 1.6, 95% CI = 1.1-3.49, p = 0.04; OR = 3.31, 95% CI = 1.3-6.8, p < 0.01; OR = 3.7, 95% CI = 1.7-6.1, p < 0.01; OR = 2.1, 95% CI = 1.7-3.3, p < 0.01; OR = 6.1, 95% CI = 4.1-9.7, p < 0.01, respectively). Conclusion. Despite much greater life expectancy of HIV/AIDS-patients, treatment-related toxicities still remain a major concern. Monitoring of lipodystrophy, as side effect of HAART, is particularly important.
    Vojnosanitetski pregled. Military-medical and pharmaceutical review 08/2014; 71(8):746-50. DOI:10.2298/VSP121016022D · 0.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: This study aimed to systematically review and quantitatively synthesize an association between HLA genotype and stavudine-induced lipodystrophy in HIV patients. Design: Systematic review and meta-analysis. Methods: A systematic search for studies that investigated the association between HLA genotype and stavudine-induced lipodystrophy was performed in six databases (i.e. PubMed, Embase, CINAHL, IPA, HuGENet, and Cochrane Library). A meta-analysis was conducted to determine the association between specific HLA genotypes and stavudine-induced lipodystrophy by using a random-effects model. Quality assessments were performed using Downs and Black checklist. Potential sources of heterogeneity were examined. Results: Two cross-sectional studies involving 439 HIV/AIDS patients who received stavudine-containing antiviral regimen (242 stavudine-induced lipodystrophy cases and 197 controls) were included. Only the prevalence of HLA-B*4001 genotype was investigated in both studies. We did not find any association between HLA-B*4001 and stavudine-induced lipodystrophy (overall OR = 3.13; 95% CI = 0.40-24.14) in a random-effects meta-analysis. A substantial heterogeneity was observed (I 2 = 79.4%, p = 0.027). Conclusions: From our systematic review of a limited number of available studies, the association between HLA-B*4001 genotype and stavudine-induced lipodystrophy cannot be concluded. Ethnicity, duration of stavudine exposure, patient selection process and small sample size may contribute to the difference in results of the included studies. Future prospective studies with a larger sample size in Thai population and different ethnic groups are needed to verify the association between HLA-B*4001 genotype and stavudine-induced lipodystrophy.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antiretroviral therapy (ART) guidelines were significantly changed by the World Health Organization in 2010. It is largely unknown to what extent these guidelines were adopted into clinical practice. This was a retrospective observational analysis of first-line ART regimens in a sample of health facilities providing ART in Kenya, Uganda, and Zambia between 2007-2008 and 2011-2012. Data were analyzed for changes in regimen over time and assessed for key patient- and facility-level determinants of tenofovir (TDF) utilization in Kenya and Uganda using a mixed effects model. Data were obtained from 29,507 patients from 146 facilities. The overall percentage of patients initiated on TDF-based therapy increased between 2007-2008 and 2011-2012 from 3% to 37% in Kenya, 2% to 34% in Uganda, and 64% to 87% in Zambia. A simultaneous decrease in stavudine (d4T) utilization was also noted, but its use was not eliminated, and there remained significant variation in facility prescribing patterns. For patients initiating ART in 2011-2012, we found increased odds of TDF use with more advanced disease at initiation in both Kenya (odds ratio [OR]: 2.78; 95% confidence interval [CI]: 1.73-4.48) and Uganda (OR: 2.15; 95% CI: 1.46-3.17). Having a CD4 test performed at initiation was also a significant predictor in Uganda (OR: 1.43; 95% CI: 1.16-1.76). No facility-level determinants of TDF utilization were seen in Kenya, but private facilities (OR: 2.86; 95% CI: 1.45-5.66) and those employing a doctor (OR: 2.86; 95% CI: 1.48-5.51) were more likely to initiate patients on TDF in Uganda. d4T-based ART has largely been phased out over the study period. However, significant in-country and cross-country variation exists. Among the most recently initiated patients, those with more advanced disease at initiation were most likely to start TDF-based treatment. No facility-level determinants were consistent across countries to explain the observed facility-level variation.
    PLoS ONE 01/2015; 10(3):e0120350. DOI:10.1371/journal.pone.0120350 · 3.53 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014

Similar Publications